
|Videos|June 2, 2014
Are Expensive New Hepatitis C Drugs Worth the High Cost?
Author(s)Davy James, Associate Editor
Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.
Advertisement
Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.
This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
PBM Reform Within 2026 Appropriations Bill Signed Into Law
2
Most Favored Nation Drug Pricing: Analysis and Implications
3
From CAR T to Gene Therapy, Pharmacists Prepare for What’s Next at the 2026 Tandem Meeting
4
Q&A: First-in-Class NSD2 Inhibitor KTX-1001 Shows Promise in High-Risk Multiple Myeloma
5


























